Your browser doesn't support javascript.
loading
A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.
Bahreyni, Amirhossein; Liu, Huitao; Mohamud, Yasir; Xue, Yuan Chao; Fan, Yiyun Michelle; Zhang, Yizhuo Lyanne; Luo, Honglin.
Affiliation
  • Bahreyni A; Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
  • Liu H; Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
  • Mohamud Y; Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
  • Xue YC; Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
  • Fan YM; Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
  • Zhang YL; Department of Pathology and Laboratory of Medicine, University of British Columbia, Vancouver, BC, V6Z 1Y6, Canada.
  • Luo H; Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
BMC Med ; 21(1): 193, 2023 05 24.
Article in En | MEDLINE | ID: mdl-37226233
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oncolytic Viruses / Melanoma Limits: Animals Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oncolytic Viruses / Melanoma Limits: Animals Language: En Year: 2023 Type: Article